Posts Tagged: "Canada"

After receiving Royal Assent on June 29, 2012, the provisions of Bill C-11 came into force on November 7, 2012. Titled the Copyright Modernization Act, it has garnered the nickname “Canada’s SOPA” by some media outlets (1), referring to the highly contentious Stop Online Piracy Act bill introduced in the US House of Representatives that led to both physical and digital(2) protests. Yet despite such bold claims, the Canadian amendment to the copyright act is a largely innocuous piece of legislation that falls in line with its stated objectives.

The Supreme Court of Canada rendered a decision on November 8, 2012 effectively canceling Viagra® Canadian patent a year and a half before its natural expiration date. This ends Pfizer’s exclusivity on the blockbuster erectile disfunction drug and opens the market up to generics. While certainly a press- worthy event, this decision does not change the Canadian patent landscape – but rather reinforces it.

This case started back in 2006, when the newspaper publishers took Google to court, stating that the popular search engine was infringing on their copyright. They had been trying to get Google to compensate them for using their online content, claiming that as more and more readers turned to the Internet to get their news, less and less readers were utilizing their printed versions. Under the new agreement, Google will team up with the Rossel Group, a major media group in Brussels that owns some of the top newspapers such as Le Soir and L’Echo; and the IPM Group which puts out publications L’Avenir and La Libre Belgique.

Americans cannot be expect to either personally or through their health insurance bear the burden associated with solely providing the return on investment required by investors to prompt pharmaceutical companies into the marketplace. Whether Americans pay through exorbitant prices out of pocket, or they pay through high priced health insurance premiums, there is no doubt that Americans subsidize individuals all around the world who pay far less than we pay in the United States. This is not a patent problem, but rather it is a government problem. Rather than seize control of the U.S. health care industry government should have tackled the underlying drivers of the cost, and a great place to start would have been in the staggeringly disparate cost of drugs between the U.S. and virtually every other country around the world.

For 2010 the US Trade Representative reviewed 77 trading partners for this year’s Special 301 Report, and placed 41 countries on either the Priority Watch List, Watch List, or the Section 306 monitoring list. The Priority Watch List for 2010 names the following countries:China, Russia, Algeria, Argentina, Canada, Chile, India, Indonesia, Pakistan, Thailand and Venezuela.